Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 539

2.

HER2/neu in systemic therapy for women with breast cancer: a systematic review.

Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M.

Breast Cancer Res Treat. 2008 May;109(2):209-29. Epub 2007 Jul 17. Review.

PMID:
17636396
3.

Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.

Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.

Cancer. 2007 Aug 1;110(3):509-17.

4.

Serum HER2 and CA 15-3 in breast cancer patients.

Baskić D, Ristić P, Pavlović S, Arsenijević N.

J BUON. 2004 Jul-Sep;9(3):289-94.

PMID:
17415828
5.

Primarily tamoxifen-unresponsive, steroid receptor-positive breast cancer may respond to an aromatase inhibition: a pilot study.

Nesković-Konstantinović Z, Susnjar S, Nikolić-Vukosavljević D, Jovanović D, Vasović S, Stamatović L, Gavrilović D.

J BUON. 2005 Jan-Mar;10(1):53-8.

PMID:
17335132
6.

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2007 Dec;106(2):181-9. Epub 2007 Jan 27.

PMID:
17260090
7.

Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.

Mottolese M, Orlandi G, Sperduti I, Merola R, Buglioni S, Di Benedetto A, Pinnarò P, Perracchio L, Venturo I, Cognetti F, Cianciulli A.

Am J Surg Pathol. 2007 Feb;31(2):247-54.

PMID:
17255770
8.

Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.

Morrison LE, Jewell SS, Usha L, Blondin BA, Rao RD, Tabesh B, Kemper M, Batus M, Coon JS.

Genes Chromosomes Cancer. 2007 Apr;46(4):397-405.

PMID:
17243161
9.

The role of c-erbB-2 expression on the survival of patients with small-cell lung cancer.

Canoz O, Ozkan M, Arsav V, Er O, Coskun HS, Soyuer S, Altinbas M.

Lung. 2006 Sep-Oct;184(5):267-72.

PMID:
17235726
10.

Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.

Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M.

Cancer. 2007 Feb 1;109(3):496-501.

11.
12.

Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.

Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ.

Br J Cancer. 2006 Nov 20;95(10):1334-41. Epub 2006 Oct 31.

13.

Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.

Ciocca DR, Gago FE, Fanelli MA, Calderwood SK.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):32-40. Epub 2006 Oct 17. Review.

PMID:
17049840
14.

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.

Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A.

Cancer. 2006 Nov 15;107(10):2337-45.

15.

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.

Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M.

Br J Cancer. 2006 Oct 23;95(8):998-1004.

16.

c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.

Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.

Tumori. 2006 Jul-Aug;92(4):311-7.

PMID:
17036522
17.

Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.

Witzel I, Thomssen C, Krenkel S, Wilczak W, Bubenheim M, Pantel K, Neumann R, Jänicke F, Müller V.

Int J Biol Markers. 2006 Jul-Sep;21(3):131-40.

PMID:
17013794
18.

Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.

Francis G, Beadle G, Thomas S, Mengersen K, Stein S.

Pathology. 2006 Oct;38(5):391-8.

PMID:
17008275
19.
20.

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.

Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S.

Cancer. 2006 Oct 15;107(8):1801-11.

Supplemental Content

Support Center